However, the efficacy of PARP inhibitor treatments in patients with BRCAness (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, PALB2, RAD50, RAD51, RAD51C, and RTEL1), or in HRD PDAC patients, remains unclear [106]. The gene discussed is CHEK2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.